Elan, Wyeth abandon top dose of Alzheimer’s drug (Reuters)
Reuters - Irish drugmaker Elan and its U.S. partner Wyeth have decided to stop testing the highest dose of their experimental Alzheimer’s drug bapineuzumab in final-stage Phase III studies, they said Thursday.
Original post by Reuters







You must be logged in to post a comment.